Company profile: Provista Diagnostics
1.1 - Company Overview
Company description
- Provider of blood-based diagnostic tests focused on oncology, including Videssa Breast Cancer Test combining serum protein biomarkers and tumor-associated autoantibodies for high-accuracy detection in women with abnormal imaging findings. Also offers COVID-19 PCR testing with same-day results from car-based collection, Long COVID panel, FDA-EUA real-time qPCR respiratory tests, UTI PCR testing, and wound infection testing with antibiotic resistance assessment.
Products and services
- Videssa Breast Cancer Blood Test: A blood-based test engineered to detect breast cancer with high accuracy in women with abnormal imaging findings, integrating serum protein biomarkers with tumor-associated autoantibodies
- Respiratory Testing: FDA-EUA approved real-time qPCR tests for various respiratory infections using any collection method, supporting flexible specimen collection while maintaining regulatory-compliant diagnostic performance
- The Long COVID Panel: A multi-assay diagnostic panel combining three distinct tests to assess the impact of post-acute sequelae of SARS-CoV-2 infection (PASC) in affected individuals
Key contacts
🔒
🔒
Financial details
🔒
1.2 - Competitors and similar companies to Provista Diagnostics
Tavec Pharma
HQ: Canada
Website
- Description: Provider of injectable cancer therapies using exosome-mediated delivery technology. The company enables delivery by injection of anti-cancer molecules, including regulatory RNA, directly to cancer cells to disrupt growth and metastasis.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Tavec Pharma company profile →
MultiVir
HQ: United States
Website
- Description: Provider of clinical-stage gene therapies, including investigational Ad-p53 and Ad-IL24 tumor suppressor immune gene therapies delivering normal genes into tumors to restore suppressor functions and stimulate anti-tumor responses; an Ad-p53 dendritic cell therapeutic vaccine; and combination regimens with anti-PD-1/PD-L1 for recurrent/metastatic cancers and advanced melanoma.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full MultiVir company profile →
Verinata Health
HQ: United States
Website
- Description: Provider of non-invasive tests for early identification of fetal chromosomal abnormalities, using proprietary technologies to enhance maternal and fetal health and reduce anxiety associated with the current multi-step process and false positives.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Verinata Health company profile →
KSQ Therapeutics
HQ: United States
Website
- Description: Provider of CRISPR-enabled drug discovery and development, offering KSQ-4279, a USP1 inhibitor in Phase 1 for advanced solid tumors targeting DNA damage repair; eTIL autologous cell therapies (KSQ-001, KSQ-004) engineered for enhanced tumor killing in solid tumors; the CRISPRomics platform for target identification in oncology and autoimmune diseases; CRISPR2 guide-pairing technology; and the ExPRESS process for eTIL manufacturing.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full KSQ Therapeutics company profile →
Chroma Medicine
HQ: United States
Website
- Description: Provider of genetic medicines built on an epigenetic editing platform that uses programmable editors to silence, activate, or regulate multiple genes by controlling chromatin conformation; single-dose genomic medicines for precise, predictable, durable treatment; multiplex epigenetic editing to enhance allogeneic CAR T cells; and a PCSK9-targeted editor to lower cholesterol and LDL-C.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Chroma Medicine company profile →
🔒
2.M&A buyers
2.1 Potential strategic acquirers in the sector
🔒
🔒
🔒
🔒
View all strategic buyers with complete profiles
Start Free Trial →
2.2 - Strategic buyer groups for Provista Diagnostics
🔒
Buyer group 1: ████████ ████████
●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒
View all companies in this group
Request Free Trial Now →
🔒
Buyer group 2: ████████ ████████
●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒
View all companies in this group
Request Free Trial Now →
🔒
Buyer group 3: ████████ ████████
●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒
View all companies in this group
Request Free Trial Now →
🔓 Unlock all detailed buyer group breakdowns with complete company profiles
Start Free Trial →
3. Investors and private equity firms
3.1 - Buyout funds investing in similar companies to Provista Diagnostics
2.2 - Growth funds investing in similar companies to Provista Diagnostics
🔒
View all growth equity funds with complete profiles
Start Free Trial →
4 - Top valuation comps for Provista Diagnostics
4.2 - Public trading comparable groups for Provista Diagnostics
🔓 Unlock all public trading comparable groups with complete valuation data
Start Free Trial →